Despite the promising findings that the currently approved chimeric antigen receptor T-cell (CAR-T) immuno-oncology (I-O) therapies – Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) – are beneficial, practical challenges associated with their pricing and reimbursement remain.
New research from analytics company GlobalData points out that, currently, Novartis’ (NOVN: VX) Kymriah and Gilead/Kite Pharma/Gilead Sciences’ (Nasdaq: GILD) Yescarta are the only CAR-T cell therapies available in the US market. The labels for both drugs contain boxed warnings for severe adverse events - cytokine release syndrome as well as neurologic toxicities.
Upon launch, Kymriah (August 2017) and Yescarta (October 2017) were priced at $475,000 and $373,000 per treatment, respectively, placing these among the highest-priced drugs on the oncology market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze